Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00374426 · ClinicalTrials.gov registry record · Phase 4
Preventing Depression Recurrence in Diabetes
A Phase 4 study of Diabetes and Major Depression, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 4
- Development phase
- 262
- Enrollment target
- 1
- Study location
NCT00374426 is a Phase 4 study of Diabetes and Major Depression that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 262 participants, below the 3,027-participant average among 338 other Diabetes trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00374426, a Phase 4 study of Diabetes and Major Depression, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 262 participants
- Enrollment target
- 1
- Study location
Study Summary
To study the effectiveness of sertraline (Zoloft) in treating depression in adults with diabetes. The study will also determine whether depressed diabetic patients who have successfully responded to sertraline (Zoloft) are more likely to have depression recur if the sertraline (Zoloft) is discontinued.
Conditions Studied
Interventions
- DRUG sertraline
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 262 participants |
| Start Date | 1998-03 |
| Est. Completion | 2004-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00374426
The ClinicalTrials.gov registry entry for NCT00374426 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 262 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,027-participant average among 338 other Diabetes trials with a reported enrollment target (91% lower). The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which sertraline is the first listed.
NCT00374426 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT00374426 about?
NCT00374426 is a clinical study titled "Preventing Depression Recurrence in Diabetes". To study the effectiveness of sertraline (Zoloft) in treating depression in adults with diabetes. The study will also determine whether depressed diabetic patients who have successfully responded to sertraline (Zoloft) are more likely to have depression recur if the sertraline (Zoloft) is discontinu...
What is the current status of trial NCT00374426?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 262 participants. The study started on 1998-03. Estimated completion is 2004-10.
What conditions does trial NCT00374426 study?
This clinical trial studies the following conditions: Diabetes, Major Depression.
What interventions are being tested in trial NCT00374426?
The interventions under investigation include: sertraline (DRUG).
Who is sponsoring clinical trial NCT00374426?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00374426 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients
RECRUITING · Phase 4
-
Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes
RECRUITING · Phase 4
-
Depression-Diabetes Mechanisms: Urban African Americans
COMPLETED · Phase 4
-
The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers
COMPLETED · Phase 4
-
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
COMPLETED · Phase 4
-
Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients From the Hospital
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.